We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-8.6%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$901M
AUM Growth
-$215M
Cap. Flow
-$75.2M
Cap. Flow %
-8.35%
Top 10 Hldgs %
51.77%
Holding
78
New
10
Increased
19
Reduced
15
Closed
15

Top Buys

1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$17.3M
2
HRTX icon
Heron Therapeutics
HRTX
+$16.5M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
4
VCYT icon
Veracyte
VCYT
+$13.4M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.22M

Top Sells

1
NVDQ
Novadaq Technologies Inc.
NVDQ
+$43.2M
2
ANGO icon
AngioDynamics
ANGO
+$23.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$18.9M
4
DVAX
Dynavax Technologies
DVAX
+$14.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13M

Sector Composition

1 Healthcare 88.9%
2 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVRO
51
DELISTED
NEVRO CORP.
NVRO
$3.15M 0.35%
43,281
-7,274
-14% -$623K
MDWD icon
52
MediWound
MDWD
$188M
$2.9M 0.32%
90,443
+14,588
+19% +$595K
NVDQ
53
DELISTED
Novadaq Technologies Inc.
NVDQ
$2.89M 0.32%
407,188
-4,767,021
-92% -$43.2M
RDHL
54
Redhill Biopharma
RDHL
$4.29M
$2.63M 0.29%
252
-465
-65% -$5.57M
CFRX
55
DELISTED
ContraFect Corporation
CFRX
$2.5M 0.28%
1,786
– –
PTN
56
Palatin Technologies
PTN
$16.2M
$1.94M 0.22%
+3,077
New +$2.14M
CGNT
57
DELISTED
Cogentix Medical, Inc.
CGNT
$1.51M 0.17%
+753,773
New +$1.54M
TRUP icon
58
Trupanion
TRUP
$1.16B
$1.04M 0.12%
67,065
-91,535
-58% -$1.47M
WINT
59
DELISTED
Windtree Therapeutics Inc
WINT
$972K 0.11%
777,797
– –
DXTR
60
DELISTED
Dextera Surgical Inc.
DXTR
$803K 0.09%
836,367
-7,800
-0.9% -$11.7K
SSKN
61
DELISTED
Strata Skin Sciences
SSKN
$423K 0.05%
19,228
– –
ASRT
62
DELISTED
Assertio
ASRT
– –
-6,325
Closed -$9.47M
DVAX
63
DELISTED
Dynavax Technologies
DVAX
– –
-1,347,810
Closed -$14.1M
HRTX icon
64
CALL
Heron Therapeutics
HRTX
$89.1M
– –
-300,000
Closed -$5.17M
PHIO icon
65
Phio Pharmaceuticals
PHIO
$12M
– –
-5
Closed -$585K
TNDM icon
66
Tandem Diabetes Care
TNDM
$1.17B
– –
-33,430
Closed -$2.56M
XBI icon
67
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-500,000
Closed -$33.1M
TRVN
68
DELISTED
Trevena, Inc.
TRVN
– –
-787
Closed -$3.32M
ISEE
69
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-410,000
Closed -$18.9M
CSII
70
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-230,532
Closed -$5.47M
XENT
71
DELISTED
Intersect ENT, Inc
XENT
– –
-638,600
Closed -$10.1M
CASM
72
DELISTED
CAS Medical Systems, Inc.
CASM
– –
-562,030
Closed -$972K
ANTH
73
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-144,334
Closed -$3.64M
AEGR
74
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-4,361,291
Closed -$13M
QLTI
75
DELISTED
QLT Inc
QLTI
– –
-5,269,831
Closed -$10.9M
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Broadfin Capital held 78 positions worth $901M, down 19% from $1.12B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital withdrew a net $75.2M in Q4 2016, closing 15 positions and reducing 15 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier, followed by Financials.

Against the trend, Broadfin Capital opened a new position in Novelion Therapeutics Inc. Common Shares worth $16.4M.

  • Broadfin Capital's largest Q4 2016 buy was Novelion Therapeutics Inc. Common Shares: 1,948,554 shares worth $16.4M.
  • Broadfin Capital added most to Heron Therapeutics in Q4 2016, an estimated $16.5M increase.
  • Broadfin Capital's biggest Q4 2016 reduction was Novadaq Technologies Inc., cutting an estimated $43.2M.
  • Broadfin Capital fully exited IVERIC bio, Inc. Common Stock in Q4 2016, selling an estimated $18.9M.
  • Broadfin Capital's ten largest holdings make up 52% of its $901M portfolio in Q4 2016.
  • Broadfin Capital opened 10 new positions and closed 15 in Q4 2016.
  • Broadfin Capital's portfolio value fell 19% quarter-over-quarter to $901M.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.